Geneva, Aug. 29 -- International Clinical Trials Registry received information related to the study (NCT07120464) titled 'Clinical Study on Immunogenicity and Safety of Lyophilized Vero Cell-Derived Human Rabies Vaccine in Special Populations' on Aug. 6.
Study Type: Observational
Primary Sponsor: Liaoning Chengda Biotechnology CO., LTD
Condition:
Rabies Exposure
Immunocompromised
Chronic Disease
Intervention:
Other: Observation Only
Recruitment Status: Recruiting
Date of First Enrollment: August 15, 2025
Target Sample Size: 180
Countries of Recruitment:
China
To know more, visit https://clinicaltrials.gov/ct2/show/NCT07120464
Published by HT Digital Content Services with permission from Health Daily Digest....